Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

HeartSciences (HSCS) Cash & Equivalents (2022 - 2026)

HeartSciences' Cash & Equivalents history spans 5 years, with the latest figure at $3.4 million for Q1 2026.

  • For Q1 2026, Cash & Equivalents rose 30.83% year-over-year to $3.4 million; the TTM value through Jan 2026 reached $3.4 million, up 30.83%, while the annual FY2025 figure was $1.1 million, 81.07% down from the prior year.
  • Cash & Equivalents reached $3.4 million in Q1 2026 per HSCS's latest filing, up from $2.0 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $7.1 million in Q1 2024 to a low of $100144.0 in Q4 2023.
  • Average Cash & Equivalents over 5 years is $2.9 million, with a median of $2.7 million recorded in 2025.
  • Peak YoY movement for Cash & Equivalents: crashed 96.74% in 2023, then soared 3946.29% in 2024.
  • A 5-year view of Cash & Equivalents shows it stood at $3.1 million in 2022, then plummeted by 96.74% to $100144.0 in 2023, then skyrocketed by 3946.29% to $4.1 million in 2024, then plummeted by 51.85% to $2.0 million in 2025, then skyrocketed by 74.11% to $3.4 million in 2026.
  • Per Business Quant, the three most recent readings for HSCS's Cash & Equivalents are $3.4 million (Q1 2026), $2.0 million (Q4 2025), and $2.8 million (Q3 2025).